Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 28, 2024iScienceOpen Access

High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YFYu FujiwaraTokyo Medical and Dental UniversitySKShumei KatoUC San Diego Health SystemDNDaisuke NishizakiUC San Diego Health System

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fujiwara et al. (2024) studied this question.

synapsesocial.com/papers/68e71ed9b6db643587698953https://doi.org/10.1016/j.isci.2024.109632
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)2018 · 393 citations
  2. 2Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy2023 · 9 citations
  3. 3Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection2008 · 149 citations
  4. 4Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated2023 · 32 citations
  5. 5Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy2022 · 310 citations